Please use this identifier to cite or link to this item:
|Title:||Treatment of steroid-resistant acute liver transplant rejection with Basiliximab|
|Source:||Fernandes, M.L., Lee, Y.M., Sutedja, D., Wai, C.T., Isacc, J., Prabhakaran, K., Lim, S.G., Lee, K.H. (2005). Treatment of steroid-resistant acute liver transplant rejection with Basiliximab. Transplantation Proceedings 37 (5) : 2179-2180. ScholarBank@NUS Repository. https://doi.org/10.1016/j.transproceed.2005.03.030|
|Abstract:||Current rescue therapies for acute steroid-resistant rejection, such as OKT3 and high-dose tacrolimus, are not uncommonly associated with side effects that contribute to significant morbidity of the patient. Basiliximab is a chimeric monoclonal antibody that acts as an interleukin-2 receptor antagonist on the surface of activated T lymphocytes. It has until now only been used as immunoprophylaxis in adult liver transplant patients. In this report, we describe the use of Basiliximab as rescue therapy in a case of acute steroid-resistant rejection in an adult living related liver transplant recipient. © 2005 by Elsevier Inc. All rights reserved.|
|Source Title:||Transplantation Proceedings|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Dec 6, 2017
WEB OF SCIENCETM
checked on Nov 18, 2017
checked on Dec 10, 2017
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.